佛慈制药(002644)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002644 佛慈制药

交易中 03-11 14:53:30

{"stockData":{"symbol":"002644","market":"SZ","secType":"STK","nameCN":"佛慈制药","latestPrice":8.96,"timestamp":1773212010000,"preClose":9.15,"halted":0,"volume":7833000,"delay":0,"changeRate":-0.0208,"floatShares":511000000,"shares":511000000,"eps":0.1157,"marketStatus":"交易中","change":-0.19,"latestTime":"03-11 14:53:30","open":9.14,"high":9.15,"low":8.9,"amount":70322300,"amplitude":0.0273,"askPrice":8.96,"askSize":339,"bidPrice":8.95,"bidSize":496,"shortable":0,"etf":0,"ttmEps":0.1157,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1773212400000},"marketStatusCode":2,"adr":0,"adjPreClose":9.15,"symbolType":"stock","openAndCloseTimeList":[[1773192600000,1773199800000],[1773205200000,1773212400000]],"highLimit":10.07,"lowLimit":8.24,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":510657000,"isCdr":false,"pbRate":2.56,"roa":"--","peRate":77.441659,"roe":"2.0%","epsLYR":0.1176,"committee":0.22185,"marketValue":4575000000,"turnoverRate":0.0153,"status":1,"floatMarketCap":4575000000},"requestUrl":"/m/hq/s/002644/tweets","defaultTab":"tweets","newsList":[{"id":"2608858705","title":"佛慈制药：467个批准文号已完成药品再注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2608858705","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608858705?lang=zh_cn&edition=full","pubTime":"2026-02-02 15:04","pubTimestamp":1770015855,"startTime":"0","endTime":"0","summary":"证券之星消息，佛慈制药(002644)02月02日在投资者关系平台上答复投资者关心的问题。投资者提问：新规下，贵公司的大量批文是不是即将面临淘汰？佛慈制药回复：您好，感谢您的关注。《中药注册管理专门规定》于2023年2月10日发布，《规定》发布后公司积极全面部署相关工作。目前，我公司持有的467个批准文号已在2024—2025年期间完成了药品再注册，且所有批准文号的药品再注册批准通知书有效期均为五年，此《规定》不影响我公司所有上市产品的正常销售。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200015065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002644","BK0239","BK0028"],"gpt_icon":0},{"id":"2608887966","title":"【私募调研记录】蠡源晟投资调研佛慈制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2608887966","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608887966?lang=zh_cn&edition=full","pubTime":"2026-02-02 08:01","pubTimestamp":1769990468,"startTime":"0","endTime":"0","summary":"根据市场公开信息及1月30日披露的机构调研信息，知名私募蠡源晟投资近期对1家上市公司进行了调研，相关名单如下：1）佛慈制药 调研纪要：公司定于2026年4月9日披露《2025年年度报告》。当前存货水平合理，周转率符合行业平均水平。2025年10月投资2000万元布局放射性同位素药物领域。并与国内多家银行和金融机构建立了长期良好的合作关系。公司以独特的眼光及全面的投资渠道为客户提供合法、安全、专业、高效的全程金融服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026020200002657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002644","BK0239"],"gpt_icon":0},{"id":"2602557489","title":"股市必读：佛慈制药（002644）1月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602557489","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602557489?lang=zh_cn&edition=full","pubTime":"2026-01-12 02:43","pubTimestamp":1768156987,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，佛慈制药报收于8.78元，上涨0.11%，换手率1.28%，成交量6.55万手，成交额5739.11万元。董秘最新回复投资者： 蚂蚁阿福新版的月活跃用户数已达3000万，用户单日提问量已超1000万。公司在天猫平台开设了官方旗舰店，与阿里健康保持长期稳定的电商业务合作。具体信息以公司年报和相关公告为准。当日关注点来自交易信息汇总：1月9日主力资金净流出552.42万元，散户资金净流入326.99万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200001083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002644"],"gpt_icon":0},{"id":"2600863060","title":"每周股票复盘：佛慈制药（002644）续聘会计师事务所获通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2600863060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600863060?lang=zh_cn&edition=full","pubTime":"2026-01-03 03:18","pubTimestamp":1767381537,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，佛慈制药报收于8.64元，较上周的8.8元下跌1.82%。本周，佛慈制药12月29日盘中最高价报8.82元。本周关注点公司公告汇总：佛慈制药2025年第二次临时股东会审议通过续聘会计师事务所议案，表决同意率达99.8005%。会议审议通过《关于续聘会计师事务所的议案》，表决结果为同意99.8005%，反对0.1853%，弃权0.0142%。甘肃金城律师事务所出具法律意见书，确认会议合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300002141.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002644","BK0028","BK0239"],"gpt_icon":0},{"id":"2595672070","title":"佛慈制药（002644）披露续聘会计师事务所议案获股东会通过，12月31日股价上涨0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595672070","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595672070?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:45","pubTimestamp":1767174305,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，佛慈制药报收于8.64元，较前一交易日上涨0.35%，最新总市值为44.12亿元。该股当日开盘8.61元，最高8.64元，最低8.53元，成交额达6694.05万元，换手率为1.52%。公司近日发布公告称，兰州佛慈制药股份有限公司于2025年12月30日召开2025年第二次临时股东会，会议审议通过了《关于续聘会计师事务所的议案》。出席会议的股东及股东代表共200人，代表股份315,754,081股，占公司有表决权总股份的61.8329%。该项议案表决结果为同意99.8005%，反对0.1853%，弃权0.0142%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100032678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002644","BK0239"],"gpt_icon":0},{"id":"2595228177","title":"佛慈制药：2025年与胖东来达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2595228177","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595228177?lang=zh_cn&edition=full","pubTime":"2025-12-31 16:30","pubTimestamp":1767169845,"startTime":"0","endTime":"0","summary":"证券之星消息，佛慈制药(002644)12月31日在投资者关系平台上答复投资者关心的问题。投资者提问：请介绍一下公司和胖东来合作情况和未来规划战略，谢谢佛慈制药回复：您好！2025年，公司与胖东来达成了战略合作，目前双方合作顺畅，合作规模不断扩大。未来公司将持续加大与胖东来等渠道的合作，推动公司实现高质量发展。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100027122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002644","BK0239"],"gpt_icon":0},{"id":"2592152638","title":"佛慈制药：面对市场承压持续降本增效","url":"https://stock-news.laohu8.com/highlight/detail?id=2592152638","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592152638?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:45","pubTimestamp":1766133920,"startTime":"0","endTime":"0","summary":"证券之星消息，佛慈制药12月19日在投资者关系平台上答复投资者关心的问题。投资者提问：23年以来，公司净利润持续下降，主要是什么原因导致，公司都采取了哪些增收措施？后期还有哪些新的利润增长点？自2022年底中药材价格出现大幅上升，进而造成中成药企业生产成本上升。2023年和2024年，受宏观经济、行业政策、市场环境、原材料价格上涨等多重因素影响，医药行业整体表现承压。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900023657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002644","BK0028"],"gpt_icon":0},{"id":"2592131772","title":"异动快报：佛慈制药（002644）12月19日10点52分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2592131772","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592131772?lang=zh_cn&edition=full","pubTime":"2025-12-19 10:55","pubTimestamp":1766112919,"startTime":"0","endTime":"0","summary":"证券之星12月19日盘中消息，10点52分佛慈制药触及涨停板。其所属行业中药目前上涨。领涨股为维康药业。该股为医药，中药，流感概念热股，当日医药概念上涨1.49%，中药概念上涨1.4%，流感概念上涨1.18%。12月18日的资金流向数据方面，主力资金净流入26.77万元，占总成交额0.76%，游资资金净流出194.21万元，占总成交额5.51%，散户资金净流入167.44万元，占总成交额4.75%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900010658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002644","BK0239","BK0028"],"gpt_icon":0},{"id":"2591730786","title":"佛慈制药：加强市值管理推动高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2591730786","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591730786?lang=zh_cn&edition=full","pubTime":"2025-12-16 08:42","pubTimestamp":1765845734,"startTime":"0","endTime":"0","summary":"证券之星消息，佛慈制药(002644)12月15日在投资者关系平台上答复投资者关心的问题。投资者提问：国企改革市值管理公司怎么考核标准，公司大股东收购价格9.55元，目前股价不足8.5元，是否存在国有资产贬值问题和风险，谢谢佛慈制药回复：您好！二级市场股价走势受多重因素影响，具有不确定性。公司将加强市值管理，通过提升经营业绩、规范信息披露、加强投资者关系管理、优化资本结构等多种方式，推动公司高质量发展，进一步增强市场信心与价值认同。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600005963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002644","BK0239","BK0028"],"gpt_icon":0},{"id":"2590511012","title":"佛慈制药（002644）披露召开2025年第二次临时股东会通知，12月11日股价下跌1.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590511012","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590511012?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:18","pubTimestamp":1765462737,"startTime":"0","endTime":"0","summary":"截至2025年12月11日收盘，佛慈制药报收于8.55元，较前一交易日下跌1.61%，最新总市值为43.66亿元。该股当日开盘8.73元，最高8.73元，最低8.53元，成交额达3328.22万元，换手率为0.76%。公司近日发布公告称，兰州佛慈制药股份有限公司将于2025年12月30日召开2025年第二次临时股东会，会议由公司董事会召集，现场会议地点为甘肃省兰州市兰州新区华山路2289号公司办公楼五楼会议室。登记时间为2025年12月26日至29日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100041745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002644","BK0239","BK0028"],"gpt_icon":0},{"id":"2588077617","title":"佛慈制药：布局中药养生茶饮开设8家佛慈茶馆","url":"https://stock-news.laohu8.com/highlight/detail?id=2588077617","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588077617?lang=zh_cn&edition=full","pubTime":"2025-12-02 09:24","pubTimestamp":1764638658,"startTime":"0","endTime":"0","summary":"证券之星消息，佛慈制药12月01日在投资者关系平台上答复投资者关心的问题。近年来，公司积极布局大健康产品产业，先后开发了阿胶糕、袋泡茶、“一支茶”系列汉方茶饮等产品，2024年6月起布局中药养生茶饮，现已开设佛慈茶馆8家，销售特色药食同源的养生茶饮和膏方产品等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200005412.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002644","BK0239","BK0028"],"gpt_icon":0},{"id":"2586277042","title":"佛慈制药：大股东承诺五年内解决同业竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2586277042","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586277042?lang=zh_cn&edition=full","pubTime":"2025-11-28 11:36","pubTimestamp":1764300984,"startTime":"0","endTime":"0","summary":"证券之星消息，佛慈制药(002644)11月27日在投资者关系平台上答复投资者关心的问题。投资者提问：公司大股东承诺解决同业竞争问题时间窗口到什么时候，谢谢。佛慈制药回复：答：您好。公司间接控股股东甘肃省国有资产投资集团有限公司承诺在收购完成后五年内解决同业竞争问题。截至目前，该承诺尚未到期。公司积极关注该事项，如有最新进展，将及时履行信息披露义务。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800012455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002644","BK0239"],"gpt_icon":0},{"id":"2586277033","title":"佛慈制药：公司生产多种感冒止咳药品","url":"https://stock-news.laohu8.com/highlight/detail?id=2586277033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586277033?lang=zh_cn&edition=full","pubTime":"2025-11-28 11:36","pubTimestamp":1764300984,"startTime":"0","endTime":"0","summary":"证券之星消息，佛慈制药(002644)11月27日在投资者关系平台上答复投资者关心的问题。投资者提问：请介绍一下公司有什么流感止咳药，谢谢。佛慈制药回复：您好。公司常年生产的感冒类药品有板蓝根颗粒、小柴胡汤丸、川芎茶调丸、九味羌活丸、风寒感冒颗粒、风热感冒颗粒、氨咖黄敏胶囊等；抗病毒类药品有银翘解毒丸、苏合香丸、安宫牛黄丸、清瘟解毒丸等；止咳化痰类药品有二陈丸、百合固金丸、通宣理肺丸、清气化痰丸、橘红丸、宁嗽丸、参苏丸、麦味地黄丸、固本丸、黄连上清丸等。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800012454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002644","BK0239"],"gpt_icon":0},{"id":"2584212139","title":"股市必读：佛慈制药（002644）11月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2584212139","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584212139?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:05","pubTimestamp":1763571919,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，佛慈制药报收于9.22元，下跌1.39%，换手率1.33%，成交量6.8万手，成交额6300.7万元。董秘最新回复投资者： 请问10月31日的股东人数多少，谢谢董秘： 您好，根据信息披露相关规则，公司会在定期报告中披露法定要求的股东数量信息。公司联系电话8362318，邮箱dshbgs@fczy.cn。当日关注点来自交易信息汇总：11月18日主力资金净流出1095.5万元，散户资金净流入1363.12万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000000463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002644","BK0028","BK0239"],"gpt_icon":0},{"id":"2581016213","title":"股市必读：佛慈制药（002644）11月6日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2581016213","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581016213?lang=zh_cn&edition=full","pubTime":"2025-11-07 02:12","pubTimestamp":1762452734,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘，佛慈制药报收于9.05元，下跌0.88%，换手率0.74%，成交量3.79万手，成交额3434.58万元。当日关注点来自交易信息汇总：11月6日主力资金净流出470.0万元，散户资金净流入343.55万元。机构调研要点公司2025年前三季度实现营业收入6.24亿元，归属于上市公司股东净利润3,808.24万元，经营活动产生现金流量净额为9,350.52万元，同比增长677.92%。制药板块毛利率为39.12%，较去年同期上升4.65个百分点，主要得益于中药材价格下降及降本增效措施。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700001324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002644","BK0239","BK0028"],"gpt_icon":0},{"id":"2578951481","title":"佛慈制药(002644.SZ)发布前三季度业绩，归母净利润3808.24万元，同比下降2.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578951481","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578951481?lang=zh_cn&edition=full","pubTime":"2025-10-28 20:23","pubTimestamp":1761654233,"startTime":"0","endTime":"0","summary":"智通财经APP讯，佛慈制药(002644.SZ)发布2025年三季度报告，前三季度，公司实现营业收入6.24亿元，同比下降11.92%。归属于上市公司股东的净利润3808.24万元，同比下降2.54%。归属于上市公司股东的扣除非经常性损益的净利润2380.9万元，同比下降5.45%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1361534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002644"],"gpt_icon":0},{"id":"2574205661","title":"佛慈制药最新公告：拟2000万元增资科近泰基公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2574205661","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574205661?lang=zh_cn&edition=full","pubTime":"2025-10-10 18:49","pubTimestamp":1760093376,"startTime":"0","endTime":"0","summary":"佛慈制药(002644.SZ)公告称，公司为提前布局放射性同位素药物赛道，与科近泰基公司签订增资协议，以2000万元现金增资，完成后将持有科近泰基公司4.911%股权。科近泰基公司是中国科学院近代物理研究所下设的全资子公司，主要业务包括离子加速器整体方案设计等。佛慈制药表示，此次投资旨在提升公司核心竞争力，且不构成关联交易或重大资产重组。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101000032345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002644","BK0239"],"gpt_icon":0},{"id":"2571386674","title":"佛慈制药（002644）披露为全资子公司提供担保的议案，9月29日股价下跌0.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2571386674","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571386674?lang=zh_cn&edition=full","pubTime":"2025-09-29 17:32","pubTimestamp":1759138364,"startTime":"0","endTime":"0","summary":"截至2025年9月29日收盘，佛慈制药报收于8.6元，较前一交易日下跌0.12%，最新总市值为43.92亿元。该股当日开盘8.6元，最高8.63元，最低8.42元，成交额达2790.36万元，换手率为0.64%。公司于近日发布公告称，第八届董事会第九次会议于2025年9月28日召开，会议审议通过《关于为全资子公司提供担保的议案》，表决结果为6票同意，0票反对，0票弃权。具体内容详见2025年9月29日《证券时报》《证券日报》及巨潮资讯网。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092900023799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002644"],"gpt_icon":0},{"id":"2517467998","title":"佛慈制药：二级市场股价波动受多重因素影响公司生产经营正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2517467998","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517467998?lang=zh_cn&edition=full","pubTime":"2025-03-05 16:45","pubTimestamp":1741164326,"startTime":"0","endTime":"0","summary":"证券之星消息，佛慈制药(002644)03月05日在投资者关系平台上答复投资者关心的问题。投资者提问：23年3400点，佛慈制药股价到15元，现在大盘又回到3400点，佛慈制药股价一直在7元徘徊！是业绩大幅下滑吗？佛慈制药回复：感谢您的关注。二级市场股价波动受多重因素影响，公司目前生产经营正常，将于4月26日披露2024年年度报告，请您届时关注公司公告。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030500028220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002644","BK0028"],"gpt_icon":0},{"id":"2516796615","title":"陇神戎发：针对与佛慈制药的同业竞争事项，甘肃国投出具了相关承诺","url":"https://stock-news.laohu8.com/highlight/detail?id=2516796615","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516796615?lang=zh_cn&edition=full","pubTime":"2025-03-04 12:00","pubTimestamp":1741060854,"startTime":"0","endTime":"0","summary":"针对公司与佛慈制药的同业竞争事项，甘肃国投出具了相关承诺，即在该收购完成后的五年内，通过包括但不限于资产转让、一方停止相关业务、调整产品结构、设立合资公司等方式解决陇神戎发及其控制的企业与佛慈制药及其控制的企业之间现存的同业竞争问题；在解决前述同业竞争情形之前，甘肃国投将通过内部协调和控制管理，确保前述同业竞争事项不会对陇神戎发构成重大不利影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030400017837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300534","BK0028","BK0132","002644","BK0239","BK0056"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773212012130,"stockEarnings":[{"period":"1week","weight":0.0615},{"period":"1month","weight":-0.0498},{"period":"3month","weight":0.0529},{"period":"6month","weight":0.0011},{"period":"1year","weight":0.1764},{"period":"ytd","weight":0.059}],"compareEarnings":[{"period":"1week","weight":0.0001},{"period":"1month","weight":0.0142},{"period":"3month","weight":0.0571},{"period":"6month","weight":0.064},{"period":"1year","weight":0.2249},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"兰州佛慈制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"33288人(较上一季度增加8.23%)","perCapita":"15340股","listingDate":"2011-12-22","address":"甘肃省兰州市皋兰县兰州新区华山路2289号","registeredCapital":"51065万元","survey":"　　兰州佛慈制药股份有限公司的主营业务是中成药研发、生产和销售，中药材种植和销售，中药饮片加工和销售，大健康产品研发、生产和销售等业务。公司的主要产品是中药、中药材及防护用品、食品保健品、药品包装材料。目前，公司生产销售的主要产品有六味地黄丸、逍遥丸、二陈丸、香砂养胃丸、安宫牛黄丸、参茸固本还少丸、阿胶等中成药，涵盖了补益、感冒、肠胃、妇科、安神睡眠等多个类别和领域；同时，开发了逍遥汤、卿卿桃花饮等30余种药食同源养生茶饮。","listedPrice":16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"佛慈制药(002644)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供佛慈制药(002644)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"佛慈制药,002644,佛慈制药股票,佛慈制药股票老虎,佛慈制药股票老虎国际,佛慈制药行情,佛慈制药股票行情,佛慈制药股价,佛慈制药股市,佛慈制药股票价格,佛慈制药股票交易,佛慈制药股票购买,佛慈制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"佛慈制药(002644)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供佛慈制药(002644)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}